[Mary Ellen Shoup, Dairy Reporter] Preliminary clinical trial results have revealed that Tamarack Biotics’ milk-based TruActive MPC 85 ingredient has more than double the antibody response compared to soy protein sample in individuals over the age of 60, the company said. Read the full article here.
[Adi Menayang, Nutra Ingredients USA] Rich with lactoferrin and immunoglobulins, a new product on the market will bring finished product makers a protein powder that is nutritionally closest to raw milk, its maker claims. Read the full article here.
Fresno, CA, September 20, 2017 – Tamarack Biotics LLC today announced the completion of a self-affirmed “Generally Recognized as Safe” (GRAS) review of its TruActive MPC 85 product. This approval enables Tamarack to begin sales of the world’s first milk protein concentrate that contains more immune active proteins than any other product available today.
Generally recognized as safe (GRAS) is an American Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements.
Fresno, CA – September 15, 2017 – Tamarack Biotics announced the results from two clinical trials, which tested TruActive’s ability to stimulate elderly immune systems and to reduce asthma symptoms in a mouse-model experiment. TruActive is the world’s first dairy product to gain regulatory approval for an alternative to pasteurization.
Immune systems weaken with age, and until now, there has been no known way to stimulate and strengthen them. This condition is known as Immunosenescence. In cooperation with UC Davis, Tamarack completed a double-blind, placebo-controlled Tetanus vaccine response clinical trial on 35 adults over 60 years of age. Twice a day for 4 weeks, the subjects consumed 7.5 grams of TruActive or a soy protein comparator and then were administered a Tetanus vaccine. After four more weeks of consumption, blood tests confirmed the level of antibodies produced by each subject. The subjects who consumed TruActive MPC 85 averaged a 12.7-fold Tetanus antibody increase, while the subjects who consumed the soy protein only experienced a 5.8-fold increase. A similar trial conducted by UC Davis in 2010 showed only a slightly statistically significant increase in whey protein consumption compared to the same soy protein.
Bob Comstock, Tamarack Biotics’ CEO stated “The Immunosenescence clinical trial proves that TruActive MPC 85 invigorates elderly immune systems and should help keep people well. The health benefits provided by a more than doubling in vaccine response are astounding. We, and our research partners at UC Davis, were pleasantly surprised by this result and we look forward to developing retail products with our partners. ”
Additionally, a study in Switzerland investigated TruActive’s ability to reduce asthma symptoms in a mouse model experiment. Six mice in each group were fed increasing levels of UHT milk, raw milk or TruActive MPC 85 for 6 weeks. During the final two weeks, the mice were exposed to house dust mite extract 3 times per week. Asthma symptom severity was measured by airway Eosinophil concentration and the study proved TruActive MPC 85 reduced Eosinophil concentration by 20% compared to UHT milk. Mr. Comstock clarified, “Asthma represents an enormous and growing problem globally. Multiple studies demonstrate that raw milk consumption, particularly early in life, reduces the number of people who develop allergies, including asthma. The scientific community believes immune active proteins provide this protective effect. The Swiss study highlights TruActive’s ability to deliver immune active proteins in a safe and effective product, which should not only protect children from developing allergies but also provide a therapeutic effect that reduces asthma symptoms.”
Tamarack Biotics’ TruActive MPC 85 product was recently recognized by Dairy Foods Magazine as a new milk-based protein today to be used in foods and beverages in the sports, early childhood and elderly nutrition categories.
The article describes the ultraviolet technology used to produce TruActive, as well as outlining our current trials.
Fresno, CA, March 1, 2017 – Tamarack Biotics LLC today announced the completion of a self-affirmed “Generally Recognized as Safe” (GRAS) for its TruActive™ NF product. This approval enables Tamarack to begin sales of the world’s first food ingredient that contains more immune active proteins than any other product available today.
Generally recognized as safe (GRAS) is an American Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements.
Bob Comstock, Tamarack Biotics CEO, stated, “Our patent pending process enables TruActive™ products to retain more of the natural compounds found in raw milk than ever before. Scientific research demonstrates that these compounds provide valuable benefits for sports and human nutrition alike. Tamarack is now conducting or planning three clinical trials to prove the benefits our products provide for elderly vaccine response, allergy prevention and therapeutic impact on asthma. The GRAS approval we received today represents a critical step in our ability to positively impact people’s health”.
About Tamarack Biotics
Tamarack Biotics develops and produces dairy-based food ingredients that retain more of the immune active proteins and other thermally sensitive compounds than any other food ingredient. Tamarack Biotics utilizes non-thermal pathogen reduction and low-temperature drying technologies that fully dry milk and milk concentrates into stable powders at temperatures low enough to protect the thermally sensitive compounds, while achieving the same safety standards as traditionally pasteurized products.
Disclaimer
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as “believes,” “projects,” “anticipates,” “forecasts,” and the like. These statements are based on the Companyʼs estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Companyʼs periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.
Fresno, CA 29 October 2016 – Today at the UC Davis hosted, International Milk Genomics Conference, Dr. Kasper Hettinga, of Wageningen University in the Netherlands, presented a paper on titled Damage to potential allergy-preventing proteins by regular heating and UVC treatment, which featured results from research jointly conducted by Dr. Hettinga and Tamarack Biotics. Dr. Hettinga’s results demonstrated the ability of UVC to protect the immune active proteins, which are thought to be responsible for raw milk’s ability to prevent children from developing allergies.
Bob Comstock, Tamarack Biotics CEO stated, “the research conducted by The PASTURE Team including Erika von Mutius of University Hospital Munich, clearly demonstrated that raw milk consumption, as opposed to living on a farm, prevented children from developing allergies. We hope to extend this research into a commercial product that contains these same allergy-preventing compounds through our innovative non-thermal pathogen reduction and low-temperature drying technologies. Dr. Hettinga’s work proves the ability of UVC to protect these immune active proteins, which are thought to be responsible for raw milk’s allergy preventing ability”.
About Tamarack Biotics
Tamarack Biotics develops and produces dairy-based food ingredients that retain more of the immune active proteins and other thermally sensitive compounds than any other food ingredient. Tamarack Biotics utilizes non-thermal pathogen reduction and low-temperature drying technologies that fully dry milk and milk concentrates into stable powders at temperatures low enough to protect the thermally sensitive compounds, while achieving the same safety standards as traditionally pasteurized products.
Disclaimer
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as “believes,” “projects,” “anticipates,” “forecasts,” and the like. These statements are based on the Company’s estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Company’s periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.
Fresno, CA, 2 Aug 2016 – Tamarack Biotics today announced the initiation of its first clinical trial testing TruActive™ MPC 85’s ability to improve vaccine reponse in the elderly. The double-blind, placebo-controlled clinical trial, conducted in conjunction with UC Davis, will investigate whether elderly Pertussis vaccine response can be improved through the use of Tamarack Biotic’s immune active protein containing product.
Researchers have known for years that immune response diminishes with age, and by the time people turn 70, only half generate the intended antibodies from a flu shot or similar vaccine. This condition, termed Immunosenescence, highlights a serious health issue for the country’s aging population. Bob Comstock, Tamarack Biotics CEO, stated “We expect to demonstrate that elderly people can remain healthier through the consumption of immune active proteins, which have never before been available. The TruActive™ line of products are the only food ingredients that contain these immune active proteins, which we believe will reduce health care costs by keeping people well”.
Mr. Comstock further stated, “the initiation of this clinical trial, with 50 subjects over the age of 60, marks an important milestone in our mult-faceted clinical trial program”. Tamarack Biotics intends to demonstrate the valuable benefits provided by immune active proteins for sports nutrition, allergy prevention and elderly health”.
About Tamarack Biotics
Tamarack Biotics develops and produces dairy-based food ingredients that retain more of the immune active proteins and other thermally sensitive compounds than any other food ingredient. Tamarack Biotics utilizes non-thermal pathogen reduction and low-temperature drying technologies that fully dry milk and milk concentrates into stable powders at temperatures low enough to protect the thermally sensitive compounds, while achieving the same safety standards as traditionally pasteurized products.
Disclaimer
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as “believes,” “projects,” “anticipates,” “forecasts,” and the like. These statements are based on the Companyʼs estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Companyʼs periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.